1
|
Cha S, Chang WK, Lee K, Han K, Paik NJ, Kim WS. Prevalence and impact of depression and anxiety among older myocardial infarction survivors: A nationwide cohort study. J Affect Disord 2024; 354:408-415. [PMID: 38479513 DOI: 10.1016/j.jad.2024.03.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 02/19/2024] [Accepted: 03/09/2024] [Indexed: 03/24/2024]
Abstract
BACKGROUND Depression and anxiety may be significant prognostic factors after myocardial infarction (MI). Thus, we investigated depression and anxiety prevalence among older MI survivors and their impact on mortality, stroke, and recurrent MI. METHODS This population-based cohort study used the Korean National Health Insurance Service database for data concerning individuals aged 66 years who participated in the National Screening Program from 2009 to 2016. Overall, 11,721 individuals with MI history and 58,605 age- and sex-matched controls were included and followed up until 2019. The presence of depression and anxiety was assessed 2 years before and after participation in the program. Mortality and major adverse outcomes, defined as a composite outcome comprising mortality, stroke, and recurrent MI, were analyzed. RESULTS Depression and anxiety prevalence among MI survivors was 20.4 % and 30.3 %, respectively. Crude odds ratios for depression and anxiety, compared with the control group, were 1.207 (1.148-1.269) and 1.078 (1.032-1.126), respectively. During the follow-up, individuals with depression, anxiety, or both showed increased hazard ratios (HRs) for mortality and major adverse outcomes; after adjustments, their HRs were 1.442 (1.182-1.759), 1.129 (0.960-1.328), and 1.498 (1.263-1.776), respectively, for mortality and 1.505 (1.289-1.758), 1.158 (1.021-1.314), and 1.530 (1.337-1.751), respectively, for major adverse outcomes. LIMITATIONS Although this was a nationwide cohort study, the MI, depression, and anxiety diagnoses were based on diagnostic codes. CONCLUSIONS Higher depression and anxiety prevalence was observed among older MI survivors. Depression and anxiety occurrence correlated with increased adverse clinical outcomes after adjustments.
Collapse
Affiliation(s)
- Seungwoo Cha
- Department of Rehabilitation Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Won Kee Chang
- Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Kyuna Lee
- Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea
| | - Kyungdo Han
- Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea
| | - Nam-Jong Paik
- Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Won-Seok Kim
- Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
| |
Collapse
|
2
|
Ganesh A, Rosentreter RE, Chen Y, Mehta R, McLeod GA, Wan MW, Krett JD, Mahjoub Y, Lee AS, Schwartz IS, Richer LP, Metz LM, Smith EE, Hill MD. Patient-reported outcomes of neurologic and neuropsychiatric symptoms in mild COVID-19: a prospective cohort study. CMAJ Open 2023; 11:E696-E705. [PMID: 37553227 PMCID: PMC10414975 DOI: 10.9778/cmajo.20220248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/10/2023] Open
Abstract
BACKGROUND Various neurologic manifestations have been reported in patients with COVID-19, mostly in retrospective studies of patients admitted to hospital, but there are few data on patients with mild COVID-19. We examined the frequency and persistence of neurologic/neuropsychiatric symptoms in patients with mild COVID-19 in a 1-year prospective cohort study, as well as assessment of use of health care services and patient-reported outcomes. METHODS Participants in the Alberta HOPE COVID-19 trial (hydroxychloroquine v. placebo for 5 d), managed as outpatients, were prospectively assessed 3 months and 1 year after their positive test result. They completed detailed neurologic/neuropsychiatric symptom questionnaires, the telephone version of the Montreal Cognitive Assessment (T-MoCA), the Kessler Psychological Distress Scale (K10) and the EuroQol EQ-5D-3L (measure of quality of life). Close informants completed the Mild Behavioural Impairment Checklist (MBI-C) and the Informant Questionnaire on Cognitive Decline in the Elderly. We also tracked use of health care services and neurologic investigations. RESULTS The cohort consisted of 198 participants (87 female [43.9%] median age 45 yr, interquartile range 37-54 yr). Of the 179 participants with symptom assessments, 139 (77.6%) reported at least 1 neurologic symptom, the most common being anosmia/dysgeusia (99 [55.3%]), myalgia (76 [42.5%]) and headache (75 [41.9%]). Forty patients (22.3%) reported persistent symptoms at 1 year, including confusion (20 [50.0%]), headache (21 [52.5%]), insomnia (16 [40.0%]) and depression (14 [35.0%]); 27/179 (15.1%) reported no improvement. Body mass index (BMI), a history of asthma and lack of full-time employment were associated with the presence and persistence of neurologic/neuropsychiatric symptoms; female sex was independently associated with both (presence: odds ratio [OR] adjusted for age, race, BMI, history of asthma and neuropsychiatric history 5.04, 95% confidence interval [CI] 1.58 to 16.10). Compared to participants without persistent symptoms, those with persistent symptoms had more hospital admissions and family physician visits, and worse MBI-C scores and less frequent independence for instrumental activities at 1 year (83.8% v. 97.8%, p = 0.005). Patients with any or persistent neurologic symptoms had worse psychologic distress (K10 score ≥ 20: adjusted OR 12.1, 95% CI 1.4 to 97.2) and quality of life (median EQ-5D-3L visual analogue scale rating 75 v. 90, p < 0.001); 42/84 (50.0%) had a T-MoCA score less than 18 at 3 months, as did 36 (42.9%) at 1 year. Participants who reported memory loss were more likely than those who did not report such symptoms to have informant-reported cognitive-behavioural decline (1-yr MBI-C score ≥ 6.5: adjusted OR 15.0, 95% CI 2.42 to 92.60). INTERPRETATION Neurologic/neuropsychiatric symptoms were commonly reported in survivors of mild COVID-19, and they persisted in 1 in 5 patients 1 year later. Symptoms were associated with worse participant- and informant-reported outcomes. Trial registration: ClinicalTrials.gov, no. NCT04329611.
Collapse
Affiliation(s)
- Aravind Ganesh
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta.
| | - Ryan E Rosentreter
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Yushi Chen
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Rahul Mehta
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Graham A McLeod
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Miranda W Wan
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Jonathan D Krett
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Yasamin Mahjoub
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Angela S Lee
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Ilan S Schwartz
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Lawrence P Richer
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Luanne M Metz
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Eric E Smith
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| | - Michael D Hill
- Departments of Clinical Neurosciences (Ganesh, McLeod, Wan, Krett, Mahjoub, Lee, Metz, Smith, Hill), Community Health Sciences (Ganesh, Smith, Hill), Medicine (Rosentreter, Hill) and Radiology (Hill), University of Calgary Cumming School of Medicine; The Hotchkiss Brain Institute (Ganesh, Metz, Smith, Hill) and The Mathison Centre for Mental Health Research & Education (Ganesh), University of Calgary, Calgary, Alta.; Departments of Dentistry (Chen) and Medicine (Mehta, Schwartz), Faculty of Medicine and Dentistry, University of Alberta; Department of Pediatrics (Richer), Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta; and Women and Children's Health Research Institute (Richer), University of Alberta, Edmonton, Alta
| |
Collapse
|
3
|
Sanchez T, Mavragani A, Lee C, Kim Y, Bae YS, Chie EK. The Association of Acute Signs and Symptoms of COVID-19 and Exacerbation of Depression and Anxiety in Patients With Clinically Mild COVID-19: Retrospective Observational Study. JMIR Public Health Surveill 2023; 9:e43003. [PMID: 36645439 PMCID: PMC9926346 DOI: 10.2196/43003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 12/30/2022] [Accepted: 01/12/2023] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND To date, the association between acute signs and symptoms of COVID-19 and the exacerbation of depression and anxiety in patients with clinically mild COVID-19 has not been evaluated. OBJECTIVE This study was designed to assess the correlation between acute signs and symptoms of COVID-19 and the exacerbation of depression and anxiety in patients with clinically mild COVID-19 at a residential treatment center in South Korea. METHODS This retrospective study assessed 2671 patients with COVID-19 admitted to 4 residential treatment centers operated by Seoul National University Hospital, South Korea, from March 2020 to April 2022. Depression and anxiety were assessed using the 2-item Patient Health Questionnaire (PHQ-2) and 2-item Generalized Anxiety Disorder (GAD-2) scale, respectively. The exacerbation of depression and anxiety symptoms was identified from the differences in PHQ-2 and GAD-2 scores between admission and discharge, respectively. The patients' clinical characteristics, including acute signs and symptoms of COVID-19, GAD-2 and PHQ-2 scores, were obtained from electronic health records. Demographic characteristics, a summary of vital signs, and COVID-19 symptoms were analyzed and compared between the patient groups with and those without exacerbated PHQ-2 and GAD-2 scores using the chi-square test. We applied logistic regression to identify the association between acute signs and symptoms of COVID-19 and the exacerbation of depression and anxiety. RESULTS Sleep disorders were associated with exacerbated depression (odds ratio [OR] 1.09, 95% CI 1.05-1.13) and anxiety (OR 1.1, 95% CI 1.06-1.14), and the sore throat symptom was associated with exacerbated anxiety symptoms (OR 1.03, 95% CI 1.00-1.07). Patients with abnormal oxygen saturation during quarantine were more likely to have exacerbated depression (OR 1.27, 95% CI 1.00-1.62), and those with an abnormal body temperature during quarantine were more likely to experience anxiety (OR 1.08, 95% CI 1.01-1.16). As anticipated, patients who experienced psychological symptoms at admission were more likely to experience depression (OR 1.91, 95% CI 1.52-2.41) and anxiety (OR 1.98, 95% CI 1.54-2.53). Meanwhile, the PHQ-2 and GAD-2 scores measured at admission revealed that lower the score, higher the possibility of exacerbation of both depression (OR 0.15, 95% CI 0.11-0.22) and anxiety (OR 0.13, 95% CI 0.10-0.19). CONCLUSIONS Results from this study suggest the importance of further interventions for patients with abnormal oxygen saturation, abnormal body temperatures, sore throat, and sleep disorder symptoms or initial psychological symptoms to mitigate the exacerbation of depression and anxiety. In addition, this study highlights the usability of short and efficient scales such as the PHQ-2 and GAD-2 in the assessment of the mental health of patients with clinically mild COVID-19 symptoms who were quarantined at home during the pandemic era.
Collapse
Affiliation(s)
| | | | - Changwoo Lee
- Office of Hospital Information, Seoul National University Hospital, Seoul, Republic of Korea
| | - Youlim Kim
- Office of Hospital Information, Seoul National University Hospital, Seoul, Republic of Korea
| | - Ye Seul Bae
- Office of Hospital Information, Seoul National University Hospital, Seoul, Republic of Korea.,Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Eui Kyu Chie
- Office of Hospital Information, Seoul National University Hospital, Seoul, Republic of Korea.,Department of Radiation Oncology, College of Medicine, Seoul National University, Seoul, Republic of Korea.,Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
4
|
Afzali A, Hatef B, Sahraei H, Meftahi GH, Khaleghi A, Jahromi GP. Changes in psychological and cognitive variables as well as cortisol levels in recovered Covid-19 patients: a longitudinal study. CURRENT PSYCHOLOGY 2023:1-10. [PMID: 36713617 PMCID: PMC9875175 DOI: 10.1007/s12144-022-04211-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 12/19/2022] [Accepted: 12/21/2022] [Indexed: 01/26/2023]
Abstract
BACKGROUND Decreased psychological and cognitive functioning is one of the complications of Covid-19 disease. We aimed to evaluate mental health, cognitive functioning, and salivary cortisol levels in Covid-19 patients with different disease severities in three 45-day intervals after recovery. METHODS 258 Covid-19 patients were assigned into three groups based on their disease severity: 112 patients in mild group, 67 patients in moderate group and 79 patients in severe group. The participants underwent psychological evaluations (including Depression, Anxiety and Stress Scale questionnaire, Beck Depression Inventory, SpeilBerger State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Inventory), cognitive assessments (The Paced Auditory Serial Addition Test) and salivary cortisol level evaluation in three 45-day periods. Non-parametric statistical methods were applied for psychological and cognitive indicators, while two-way mixed model ANOVA was used to evaluate the cortisol concentration in three replications. RESULTS The group of mild patients became more anxious and the group of moderate patients became more anxious and depressed. But all three groups of patients developed severe sleep disorders over time. For cognitive functioning, although the results showed a decrease in the correct response rate, a significant increase in the correct response rate was observed in all three groups in all three measurements. However, the response speed not only did not increase, but also decreased in severe group. Cortisol level had a markedly increasing trend in all three groups. CONCLUSION Improvement of cognitive functioning was in line with the increase in cortisol. Besides, the decrease in mental health had no effect on the cognitive functioning.
Collapse
Affiliation(s)
- Ahmad Afzali
- Student Research Committee, Baqiyatallah University of Medical Science, Tehran, Iran
| | - Boshra Hatef
- Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Hedayat Sahraei
- Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | | | - Ali Khaleghi
- Psychiatry and Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Gila Pirzad Jahromi
- Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Thompson EJ, Stafford J, Moltrecht B, Huggins CF, Kwong ASF, Shaw RJ, Zaninotto P, Patel K, Silverwood RJ, McElroy E, Pierce M, Green MJ, Bowyer RCE, Maddock J, Tilling K, Katikireddi SV, Ploubidis GB, Porteous DJ, Timpson N, Chaturvedi N, Steves CJ, Patalay P. Psychological distress, depression, anxiety, and life satisfaction following COVID-19 infection: evidence from 11 UK longitudinal population studies. Lancet Psychiatry 2022; 9:894-906. [PMID: 36244359 PMCID: PMC9560745 DOI: 10.1016/s2215-0366(22)00307-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 07/14/2022] [Accepted: 08/09/2022] [Indexed: 11/26/2022]
Abstract
BACKGROUND Evidence on associations between COVID-19 illness and mental health is mixed. We aimed to examine whether COVID-19 is associated with deterioration in mental health while considering pre-pandemic mental health, time since infection, subgroup differences, and confirmation of infection via self-reported test and serology data. METHODS We obtained data from 11 UK longitudinal studies with repeated measures of mental health (psychological distress, depression, anxiety, and life satisfaction; mental health scales were standardised within each study across time) and COVID-19 status between April, 2020, and April, 2021. We included participants with information available on at least one mental health outcome measure and self-reported COVID-19 status (suspected or test-confirmed) during the pandemic, and a subset with serology-confirmed COVID-19. Furthermore, only participants who had available data on a minimum set of covariates, including age, sex, and pre-pandemic mental health were included. We investigated associations between having ever had COVID-19 and mental health outcomes using generalised estimating equations. We examined whether associations varied by age, sex, ethnicity, education, and pre-pandemic mental health, whether the strength of the association varied according to time since infection, and whether associations differed between self-reported versus confirmed (by test or serology) infection. FINDINGS Between 21 Dec, 2021, and July 11, 2022, we analysed data from 54 442 participants (ranging from a minimum age of 16 years in one study to a maximum category of 90 years and older in another; including 33 200 [61·0%] women and 21 242 [39·0%] men) from 11 longitudinal UK studies. Of 40 819 participants with available ethnicity data, 36 802 (90·2%) were White. Pooled estimates of standardised differences in outcomes suggested associations between COVID-19 and subsequent psychological distress (0·10 [95% CI 0·06 to 0·13], I2=42·8%), depression (0·08 [0·05 to 0·10], I2=20·8%), anxiety (0·08 [0·05 to 0·10], I2=0·0%), and lower life satisfaction (-0·06 [-0·08 to -0·04], I2=29·2%). We found no evidence of interactions between COVID-19 and sex, education, ethnicity, or pre-pandemic mental health. Associations did not vary substantially between time since infection of less than 4 weeks, 4-12 weeks, and more than 12 weeks, and were present in all age groups, with some evidence of stronger effects in those aged 50 years and older. Participants who self-reported COVID-19 but had negative serology had worse mental health outcomes for all measures than those without COVID-19 based on serology and self-report. Participants who had positive serology but did not self-report COVID-19 did not show association with mental health outcomes. INTERPRETATION Self-reporting COVID-19 was longitudinally associated with deterioration in mental health and life satisfaction. Our findings emphasise the need for greater post-infection mental health service provision, given the substantial prevalence of COVID-19 in the UK and worldwide. FUNDING UK Medical Research Council and UK National Institute for Health and Care Research.
Collapse
Affiliation(s)
- Ellen J Thompson
- Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK
| | - Jean Stafford
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK.
| | - Bettina Moltrecht
- Centre for Longitudinal Studies, University College London, London, UK
| | - Charlotte F Huggins
- Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK
| | - Alex S F Kwong
- Division of Psychiatry, University of Edinburgh, Edinburgh, UK
| | - Richard J Shaw
- MRC/CSO Social & Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Paola Zaninotto
- Department of Epidemiology and Public Health, University College London, London, UK
| | - Kishan Patel
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK
| | | | - Eoin McElroy
- School of Psychology, Ulster University, Ulster, UK
| | - Matthias Pierce
- Division of Psychology and Mental Health, The University of Manchester, Manchester, UK
| | - Michael J Green
- MRC/CSO Social & Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Ruth C E Bowyer
- Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK
| | - Jane Maddock
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Kate Tilling
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - S Vittal Katikireddi
- MRC/CSO Social & Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | | | - David J Porteous
- Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK
| | - Nic Timpson
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Nish Chaturvedi
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Claire J Steves
- Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK
| | - Praveetha Patalay
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK; Centre for Longitudinal Studies, University College London, London, UK
| |
Collapse
|
6
|
Bae YS, Sung S, Lee J, Lee H, Chie EK. Building and implementing a contactless clinical trial protocol for patients with COVID-19: A Korean perspective. Front Med (Lausanne) 2022; 9:975243. [PMID: 36186782 PMCID: PMC9520334 DOI: 10.3389/fmed.2022.975243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 08/31/2022] [Indexed: 11/23/2022] Open
Abstract
Introduction To effectively manage patients with coronavirus disease 2019 (COVID-19) while minimizing contact between medical staff, clinical trial protocol that facilitates contactless patient management was designed to predict deterioration of disease condition and monitor mental health status. Methods Through consultation with infectious disease specialists and psychiatrists, this study identified main clinical indicators related to respiratory and non-respiratory outcomes, and mental health. Telehealth devices that could collect relevant data indicators were explored. The following three modes were identified: wearable devices, video calls, and online questionnaires. Clinical trial protocol was implemented to patients confirmed with COVID-19 infection and admitted to Seongnam residential treatment centers between September 1, 2021 and December 30, 2021. Data were collected from wearable devices, video calls, online questionnaires, and from electronic health records. Participant satisfaction was assessed through an online survey at the time of discharge. Results In total, 120 asymptomatic and mildly symptomatic COVID-19 patients participated in this trial. Seven types of physiological and life log data were collected from 87 patients using wearable devices, video and audio recordings, and online mental health-related questionnaire. Most participants were satisfied with the overall trial process, but perceived difficulties in using telehealth devices. Conclusion This trial collected simultaneously generated multimodal patient data using various telehealth devices in a contactless setting for COVID-19 patients. Data collected in this study will be used to build a remote patient management system based on the prediction algorithms.
Collapse
Affiliation(s)
- Ye Seul Bae
- Office of Hospital Information, Seoul National University Hospital, Seoul, South Korea
- Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea
| | - Sumi Sung
- Office of Hospital Information, Seoul National University Hospital, Seoul, South Korea
| | - Jungeun Lee
- Office of Hospital Information, Seoul National University Hospital, Seoul, South Korea
| | - Hyeonji Lee
- Office of Hospital Information, Seoul National University Hospital, Seoul, South Korea
| | - Eui Kyu Chie
- Office of Hospital Information, Seoul National University Hospital, Seoul, South Korea
- Department of Radiation Oncology, College of Medicine, Seoul National University, Seoul, South Korea
- Medical Research Center, Institute of Radiation Medicine, Seoul National University, Seoul, South Korea
- *Correspondence: Eui Kyu Chie
| |
Collapse
|
7
|
Zhang N, Hong D, Yang H, Mengxi G, Huang X, Wang A, Wang L. Risk perception, anxiety, and depression among hospital pharmacists during the COVID-19 pandemic: The mediating effect of positive and negative affect. JOURNAL OF PACIFIC RIM PSYCHOLOGY 2022. [DOI: 10.1177/18344909221101670] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
This study investigated the impacts of risk perception of COVID-19 on anxiety and depression symptoms among hospital pharmacists in China. We conducted a cross-sectional study with hospital pharmacists during the COVID-19 pandemic in China. Some 4,219 hospital pharmacists completed an online survey including demographic questions, risk perception of COVID-19, General Anxiety Disorder-7, Patient Health Questionnaire-9, and Positive and Negative Affect Schedule. Multivariate regression and mediation analyses were conducted. The results indicated that 41.9% and 29.4% of hospital pharmacists experienced mild to severe levels of anxiety and depression symptoms, respectively. In older age, a higher level of risk perception of COVID-19, and negative affect experience were risk factors, whereas positive affect experience was a protective factor for anxiety and depression symptoms among pharmacists. Experience of positive and negative affect mediated the relationship between risk perception of COVID-19 and anxiety and depression among hospital pharmacists in China. Timely mental health services need to be provided for hospital pharmacists during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Ning Zhang
- School of Public Health and the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310058, China
| | - Dongsheng Hong
- Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Hongyu Yang
- Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Guo Mengxi
- School of Public Health and the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310058, China
| | - Xin Huang
- Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Anran Wang
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China
| | - Linrun Wang
- Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| |
Collapse
|
8
|
Travis-Lumer Y, Kodesh A, Goldberg Y, Reichenberg A, Frangou S, Levine SZ. Biopsychosocial Exposure to the Covid-19 Pandemic and the Relative Risk of Schizophrenia: Interrupted Time-Series Analysis of a Nationally Representative Sample. Eur Psychiatry 2022; 65:e7. [PMID: 35067255 PMCID: PMC8853851 DOI: 10.1192/j.eurpsy.2021.2245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Studies of COVID-19 pandemic biopsychosocial exposure and schizophrenia risk showed contradictory results, were undertaken early in the pandemic, and did not consider lockdowns or COVID-19 infection. Hence, we examined the association between COVID-19 biopsychosocial exposure and incident schizophrenia. Methods An interrupted time-series study design was implemented based on Israeli electronic health records from 2013 to 2021 with national coverage. The period coinciding with the COVID-19 pandemic biopsychosocial exposures from March 2020 to February 2021 was classified as exposed, otherwise unexposed. The effect of the COVID-19 pandemic on incident schizophrenia was quantified by fitting a Poisson regression and modeling the relative risk (RR) and corresponding 95% confidence intervals (CI). Three scenarios were projected from the third lockdown to 10 months to forecast incident schizophrenia rates and their associated 95% prediction intervals (PI). Results The total population (N = 736,356) yielded 4,310 cases of incident schizophrenia over time. The primary analysis showed that the period exposed to the COVID-19 pandemic was associated with a reduced RR (RR = 0.81, 95% CI = 0.73, 0.91, p < 0.001). This conclusion was supported in 12 sensitivity analyses, including scrutinizing lockdowns and COVID-19 infection status. Two of three forecast scenarios projected an incident increase (6.74, 95% PI = 5.80, 7.84; 7.40, 95% PI = 6.36, 8.60). Conclusions The reduced risk of schizophrenia during the pandemic suggests no immediate triggering of new onsets either by the virus or the pandemic-induced psychosocial adversities. Once restrictions are lifted, the increased projected presentations have implications for clinicians and healthcare policy.
Collapse
|
9
|
Liu J, Dong F, Robinson N. State-of-the-art evidence of traditional Chinese medicine for treating coronavirus disease 2019. JOURNAL OF TRADITIONAL CHINESE MEDICAL SCIENCES 2022. [PMCID: PMC8741624 DOI: 10.1016/j.jtcms.2022.01.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Traditional Chinese medicine has widely been used internationally in the treatment of coronavirus disease 2019 (COVID-19) since January 2020. There has been great interest in initiating clinical studies testing different Chinese medicine therapies for COVID-19, but the majority of registered studies have yet to move forward due to a lack of COVID-19 patients in mainland China. The aim of this article was to systematically review the current clinical research evidence on Chinese medicine for treating COVID-19 from international and domestic bibliographic databases to reflect on the advances in this field.
Collapse
|
10
|
Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, Hafeez D, Burchill E, Saini A, Thomas L, Cross B, Hunt CK, Conti I, Ralovska S, Hussain Z, Butler M, Pollak TA, Koychev I, Michael BD, Holling H, Nicholson TR, Rogers JP, Rooney AG. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun 2021; 4:fcab297. [PMID: 35169700 PMCID: PMC8833580 DOI: 10.1093/braincomms/fcab297] [Citation(s) in RCA: 124] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 09/10/2021] [Accepted: 12/15/2021] [Indexed: 12/21/2022] Open
Abstract
The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19. For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750), we searched MEDLINE, EMBASE, CINAHL and PsycINFO to 20 February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection and in control groups where available. For each study, a minimum of two authors extracted summary data. For each symptom, we calculated a pooled prevalence using generalized linear mixed models. Heterogeneity was measured with I 2. Subgroup analyses were conducted for COVID-19 hospitalization, severity and duration of follow-up. From 2844 unique titles, we included 51 studies (n = 18 917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14-182 days). Study quality was most commonly moderate. The most prevalent neuropsychiatric symptom was sleep disturbance [pooled prevalence = 27.4% (95% confidence interval 21.4-34.4%)], followed by fatigue [24.4% (17.5-32.9%)], objective cognitive impairment [20.2% (10.3-35.7%)], anxiety [19.1% (13.3-26.8%)] and post-traumatic stress [15.7% (9.9-24.1%)]. Only two studies reported symptoms in control groups, both reporting higher frequencies in COVID-19 survivors versus controls. Between-study heterogeneity was high (I 2 = 79.6-98.6%). There was little or no evidence of differential symptom prevalence based on hospitalization status, severity or follow-up duration. Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing but indicates a particularly high prevalence of insomnia, fatigue, cognitive impairment and anxiety disorders in the first 6 months after infection.
Collapse
Affiliation(s)
- James B. Badenoch
- Barts Health NHS Trust, London, UK
- Queen Mary University of London, London, UK
| | - Emma R. Rengasamy
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Cameron Watson
- Barts Health NHS Trust, London, UK
- Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Katrin Jansen
- Department of Psychology, University of Münster, Münster, Germany
| | - Stuti Chakraborty
- Department of Physical Medicine and Rehabilitation, Christian Medical College and Hospital, Vellore, India
- Occupational Therapy Unit, Department of Physical Medicine and Rehabilitation, Christian Medical College and Hospital, Vellore, India
| | | | - Danish Hafeez
- Homerton University Hospitals Foundation Trust, London, UK
| | - Ella Burchill
- Faculty of Medicine and Life Sciences, King’s College London, London, UK
| | - Aman Saini
- Medical School, University College London, London, UK
| | - Lucretia Thomas
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | | | | | - Isabella Conti
- School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK
| | - Sylvia Ralovska
- Sofia University ‘St Kliment Ohridski’, bul, ‘Tsar Osvoboditel’ 15, Sofia, Bulgaria
| | - Zain Hussain
- Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, UK
- School of Medicine, University of Dundee, Dundee, UK
| | - Matthew Butler
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Thomas A. Pollak
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Ivan Koychev
- Department of Psychiatry, University of Oxford, Oxford, UK
- Department of Psychological Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Benedict D. Michael
- Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
- National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infection, University of Liverpool, Liverpool, UK
- Clinical Infection Microbiology and Immunology, Institute of Infection, Veterinary, and Zoological Science, University of Liverpool, Liverpool, UK
| | - Heinz Holling
- Department of Psychology, University of Münster, Münster, Germany
| | - Timothy R. Nicholson
- Section of Cognitive Neuropsychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Jonathan P. Rogers
- Division of Psychiatry, University College London, London, UK
- South London and Maudsley NHS Foundation Trust, London, UK
| | - Alasdair G. Rooney
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
| |
Collapse
|
11
|
Kim J, Hong K, Gómez Gómez RE, Kim S, Chun BC. Lack of Evidence of COVID-19 Being a Risk Factor of Alopecia Areata: Results of a National Cohort Study in South Korea. Front Med (Lausanne) 2021; 8:758069. [PMID: 34722594 PMCID: PMC8550157 DOI: 10.3389/fmed.2021.758069] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 09/14/2021] [Indexed: 12/23/2022] Open
Abstract
Background: Concerns about alopecia areata (AA) in coronavirus disease 2019 (COVID-19) patients have emerged among dermatologists. However, most of the extant kinds of literature have limited implications by relying on cross-sectional studies with restricted study subjects without the control group. Objective: Our study aims to investigate the risk of developing AA among COVID-19 patients in South Korea using national representative data. Methods: We used the National Health Insurance Service COVID-19 cohort database, comprising COVID-19 patients and the control group, all of whom were diagnosed from January 1, 2020, to June 4, 2020. Patients were defined as individuals who were confirmed as COVID-19 positive, regardless of disease severity. Controls were defined as those who were confirmed as COVID-19 negatives. People with a history of AA during the period 2015-2019 were excluded. The primary endpoint was a new diagnosis of AA (ICD-10-Code: L63). The adjusted incidence rate ratio (IRR) of developing AA was estimated using a log-link Poisson regression model based on incidence density. The model adjusted for (1) age and sex and (2) demographic variables (age, sex, place of residence, and income level). Results: A total of 226,737 individuals (7,958 [3.5%] cases and 218,779 [96.5%] controls) were included in the final analysis. The ratio of newly diagnosed AA was 18/7,958 (0.2%) in cases and 195/218,779 (0.1%) in controls. IRRs of COVID-19 patients having newly diagnosed AA compared to controls were 0.78 (95% CI: 0.48-1.27) when age and sex were adjusted for and 0.60 (95% CI: 0.35-1.03) when all demographic variables were adjusted for. Conclusion: Diagnosis of COVID-19 was not significantly associated with the development of AA even after appropriately adjusting for covariates.
Collapse
Affiliation(s)
- Jeehyun Kim
- Graduate School of Public Health, Korea University, Seoul, South Korea.,Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea.,Transdisciplinary Major in Learning Health Systems, Department of Healthcare Sciences, Graduate School, Korea University, Seoul, South Korea
| | - Kwan Hong
- Graduate School of Public Health, Korea University, Seoul, South Korea.,Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Raquel Elizabeth Gómez Gómez
- Graduate School of Public Health, Korea University, Seoul, South Korea.,Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Soojin Kim
- Graduate School of Public Health, Korea University, Seoul, South Korea.,Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea.,Transdisciplinary Major in Learning Health Systems, Department of Healthcare Sciences, Graduate School, Korea University, Seoul, South Korea
| | - Byung Chul Chun
- Graduate School of Public Health, Korea University, Seoul, South Korea.,Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea.,Transdisciplinary Major in Learning Health Systems, Department of Healthcare Sciences, Graduate School, Korea University, Seoul, South Korea
| |
Collapse
|
12
|
Park HY, Song IA, Lee SH, Sim MY, Oh HS, Song KH, Yu ES, Park HY, Oh TK. Prevalence of mental illness among COVID-19 survivors in South Korea: nationwide cohort. BJPsych Open 2021; 7:e183. [PMID: 34659793 PMCID: PMC8503052 DOI: 10.1192/bjo.2021.1001] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 07/15/2021] [Accepted: 07/16/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Mental illness among survivors of coronavirus disease 2019 (COVID-2019) during the post-illness period is an emerging and important health issue. AIMS We aimed to investigate the prevalence of mental illness and the associated factors for its development among COVID-2019 survivors. METHOD From 1 January to 4 June 2020, data were extracted from the National Health Insurance Service COVID-19 database in South Korea. Patients with COVID-19 were defined as those whose test results indicated that they had contracted the infection, regardless of disease severity. COVID-19 survivors were defined as those who recovered from the infection. The primary end-point was the development of mental illness, which was evaluated between 1 January and 1 December 2020. RESULTS A total 260 883 individuals were included in this study, and 2.36% (6148) were COVID-19 survivors. The COVID-19 survivors showed higher prevalence of mental illness than the control group (12.0% in the COVID-19 survivors v. 7.7% in the control group; odds ratio (OR) = 2.40, 95% CI 2.21-2.61, P < 0.001). Additionally, compared with the control group, the no specific treatment for COVID-19 group (OR = 2.23, 95% CI 2.03-2.45, P < 0.001) and specific treatment for COVID-19 group (OR = 3.27, 95% CI 2.77-3.87, P < 0.001) showed higher prevalence of mental illness among survivors. CONCLUSIONS In South Korea, COVID-19 survivors had a higher risk of developing mental illness compared with the rest of the populations. Moreover, this trend was more evident in COVID-19 survivors who experienced specific treatment in the hospital.
Collapse
Affiliation(s)
- Hye Yoon Park
- Department of Psychiatry, Seoul National University Hospital, South Korea
| | - In-Ae Song
- Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Republic of Korea
| | - So Hee Lee
- Department of Psychiatry, National Medical Center, Republic of Korea
| | - Min young Sim
- National Center for Disaster Trauma, National Center for Mental Health, Republic of Korea
| | - Hong Sang Oh
- Division of Infectious Disease, Department of Internal Medicine, Armed Forces Capital Hospital, Republic of Korea
| | - Kyoung-Ho Song
- Division of Infectious Disease, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Republic of Korea
| | - Eun-Seung Yu
- Department of Counseling Psychology, the Cyber University of Korea, Republic of Korea
| | - Hye Youn Park
- Department of Psychiatry, Seoul National University Bundang Hospital, Republic of Korea
| | - Tak Kyu Oh
- Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Republic of Korea
| |
Collapse
|
13
|
Park HY, Song IA, Oh TK. Insomnia Disorder Among Coronavirus Disease Survivors: A South Korean Nationwide Cohort Study. Psychiatry Investig 2021; 18:1082-1090. [PMID: 34710959 PMCID: PMC8600214 DOI: 10.30773/pi.2021.0223] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 08/29/2021] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE We investigated the prevalence and associated factors of insomnia disorder among survivors of coronavirus disease of 2019 (COVID-19). METHODS This population-based cohort study used data from the National Health Insurance Service COVID-19 cohort database from January 1 to June 4, 2020. COVID-19 patients were defined as individuals whose test confirmed that they were infected, regardless of the severity, and survivors were defined as individuals who recovered from the infection. RESULTS A total of 299,968 individuals were included in the final analysis, and 6,934 were considered as COVID-19 survivors, while the control group comprised 292,764 individuals. In the multivariable model after covariate adjustment, COVID-19 survivors had a 3.33-fold higher prevalence of insomnia disorder than the control group (odds ratio [OR]: 3.33, 95% confidence interval [CI]: 2.98-3.73; p<0.001). In the sensitivity analysis, the COVID-19 survivors with no specific treatment and the survivors with specific treatment were associated with a 3.16-fold (OR: 3.16, 95% CI: 2.77-3.59; p<0.001) and 3.89-fold (OR: 3.89, 95% CI: 3.17-4.78; p<0.001) higher prevalence of insomnia disorder than the control group. CONCLUSION In South Korea, 5.4% of COVID-19 survivors were diagnosed with insomnia disorder at 6 months follow-up. Thus, insomnia disorder is a public health issue for COVID-19 survivors.
Collapse
Affiliation(s)
- Hye Yoon Park
- Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea.,Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - In-Ae Song
- Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Tak Kyu Oh
- Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| |
Collapse
|